GHO and Ampersand Capital to acquire Avid Bioservices
The definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid.
Avid Bioservices to be acquired for $1.1B in cash by GHO, Ampersand
Avid Bioservices (NASDAQ:CDMO) has agreed to be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners through a cash deal that values the company at around $1.1B. Under the deal,
Avid Bioservices to be Acquired in $1.1 Billion Deal
Avid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization,
Avid Bioservices to be taken private by GHO, Ampersand in $1.1 billion deal
Avid Bioservices said on Wednesday that it would be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in a deal valued at about $1.1 billion. GHO and Ampersand have offered $12.
GHO Capital, Ampersand Capital to buy Avid Bioservices in $1.1bn deal
GHO Capital Partners and Ampersand Capital Partners have agreed to acquire Avid Bioservices, a biologics contract development and manufacturing organization, in an all-cash transaction valued at around $1.1 billion. Avid provides development and manufacturing services to biotechnology and pharmaceutical companies. It is based in Tustin, California.
Avid Bioservices Shares Rise After $1.1B Buyout Offer
Avid Bioservices shares were up 12% at $12.25 after getting a buyout offer from GHO Capital Partners and Ampersand Capital Partners. Under the terms of the buyout, Avid will be acquired by funds managed by GHO and Ampersand in an all-cash transaction valued at $1.
Avid Bioservices to Go Private in $1.1 Billion Deal
Avid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move forward as a private company under new owners.
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
Under the terms of the merger agreement, GHO and Ampersand would acquire all the outstanding shares held by Avid’s stockholders for $12.50 per share in cash. The per share purchase price represents a 13.
PE Hub19h
Post-election policies will fuel M&A, say dealmakers; GHO Capital and Ampersand buy Avid Bioservices for $1.1 billion
Good morning dealmakers, it’s Obey Martin Manayiti with the US edition of the Wire from the New York newsroom, filling in for ...
Avid Bioservices downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company ...
FiercePharma3d
Nektar pads wallet with $90M manufacturing plant sale to Ampersand
After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...
GlobalData on MSN2d
Nektar Therapeutics to sell Alabama facility to Ampersand
The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
Nicolle Pangis Joins Netflix as VP Advertising
Nicolle Pangis, a former head of the cable-ad-sales entity Ampersand, has joined Netflix as is vice president of ad sales ...
MyChesCo on MSN2d
Resolian Announces Leadership Changes Amid Global Expansion
Bioanalytical contract research organization Resolian has announced significant leadership changes as it continues its global expansion. Rob Stachlewitz has been named the new Chief Executive Officer, ...
Nektar Announces Definitive Agreement With Ampersand Capital Partners To Sell Its Commercial Pegylation Reagent Manufacturing Business In Alabama
Huntsville-based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in tota ...